Diederik Hentenaar

63 Erythritol air-polishing in non-surgical peri-implantits treatment Table 1. (Continued) Air-polishing Ultrasonic Rough ≥2.0 µm 1 (1.5) 5 (6.8) Type of restoration; n implants (%) Single crown 20 (30.3) 38 (52.1) Fixed partial denture 23 (34.8) 12 (16.4) Overdenture 23 (34.8) 23 (31.5) Screw- or cement-retained restoration; n implants (%) Screwed 47 (71.2) 52 (71.2) Cemented 19 (28.8) 21 (28.8) Implants placed in maxilla or mandible; n implants (%) Maxilla 36 (54.5) 46 (63.0) Mandible 30 (45.5) 27 (37.0) Implants placed anterior posterior; n implants (%) Anterior (central incisor to cuspid) 28 (42.4) 29 (39.7) Posterior (premolar/molar) 38 (57.6) 44 (60.3) At 3-month evaluation, 14 patients (18%) showed a successful treatment outcome: 4 patients (5 implants) in the air-polishing group and 10 patients (18 implants) in the ultrasonic group. Peri-implant assessment of these 14 patients took place at 6, 9 and 12 months follow-up. The distribution of sites with BoP in successful implants is shown in table 4. The remaining 62 patients with an unsuccessful treatment outcome at the 3-month evaluation discontinued the current study but were invited to continue in a surgical follow-up protocol. Primary outcome At 3 month evaluation, no statistical significant difference for mean BoP was found between air-polishing (49.8%±31.5) and ultrasonic therapy (48.1% ±29.0). Secondary outcomes No significant differences between both groups at 3 month evaluation were found for the secondary clinical peri-implant parameters; SoP, Plq and PPD, neither in the crude nor in the adjusted analysis, see Table 5. In addition, patients succeeded to lower mean levels of periodontal full mouth BoP and plaques scores (BoP reduced from 11.8% ±10.5 to 9.2% ±7.0 at T3, p = 0.032, plaque score reduced from 27.3% (±17.9) to 22.6 (±16.8), p = 0.013, at T3) (see Table 3a). No group differences were seen for mean marginal bone loss (at the mesial and/or distal site) or microbiological outcomes at 3 month evaluation (see Table 3a & 5). Patients that showed more than 0.5mm progressive bone loss at T3 3